Highest-materiality recent filing
Company held investor call on April 30, 2026 at 1:00 p.m. PT to provide corporate and clinical update.
CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock
Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.
CytoDyn raises $17.5M via private placement of 81.4M units at $0.2153 per unit
Private placement of ~81.4M units (share + warrant) to accredited investors for ~$17.5M in cash.
CytoDyn agrees to settle securities class action for $500K cash and 49M shares
Settlement in principle: $500,000 cash plus 49 million shares for dismissal of all claims.
CytoDyn shareholders approve increase in authorized shares to 2.25B; all directors reelected
Authorized common stock increased from 1.75B to 2.25B shares; approved 671,591,768 For vs 69,716,006 Against.
CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months
Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
CytoDyn swaps auditor from Marcum to CBIZ after Marcum resignation; no accounting disagreements
Marcum LLP resigned as independent auditor effective May 14, 2025; CBIZ CPAs P.C. engaged same day for FY ending May 31, 2025.
CytoDyn appoints Robert E. Hoffman as CFO effective May 15, 2025
Hoffman replaces interim CFO Mitch Cohen; Cohen resigns effective May 12 with last day May 30.
CytoDyn shareholders elect all director nominees at 2024 Annual Meeting
Tanya Durkee Urbach, Stephen M. Simes, Ryan M. Dunlap, Lishomwa C. Ndhlovu, and Karen J. Brunke elected as directors for one-year terms.
CytoDyn settles Amarex lawsuit for $12M cash payment and $14M liability elimination
Amarex to pay CytoDyn $12 million total, with $10 million received upon execution.
CytoDyn appoints Marcum LLP as new independent auditor effective June 28
Marcum LLP engaged as independent registered public accounting firm effective June 28, 2024.
CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%
52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.
CytoDyn dismisses BF Borgers as auditor after SEC permanent bar; replacement search underway
Dismissed BF Borgers on May 6, 2024, following SEC order on May 3 permanently barring the firm.
CytoDyn restructures $43.8M Samsung debt; payment contingent on revenue
Total balance of $43,821,231.32 restructured; only $250,000 due by Dec 31, 2024; remainder contingent on 20% of qualifying annual revenue.
Private placement of ~20.6M units at ~$0.17/unit raised ~$3.5M; each unit = 1 share + 5-yr warrant at $0.21.
CytoDyn appoints Jacob Lalezari as permanent CEO, names Mitchell Cohen interim CFO
Jacob Lalezari appointed CEO effective Jan 26, 2024; previously interim CEO since Nov 2023.
CytoDyn settles class action over director removal clause; pays $59,500
Class action challenged 'Only With Cause Clause' for removing directors; court invalidated it in January 2022.
Partial clinical hold from March 2022 lifted by FDA in December 2023.
Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.
CytoDyn appoints Jacob Lalezari as interim CEO, effective Nov 17, 2023
Dr. Lalezari appointed interim CEO; Antonio Migliarese ceases interim President but remains CFO.
CytoDyn shareholders approve authorized common stock increase to 1.75B shares
Authorized shares increased from 1.35B to 1.75B, approved by 504.7M for vs 42.6M against.
CytoDyn remains under FDA clinical hold; seeks authorized share increase for viability
FDA partial clinical hold still unresolved; comprehensive resubmission made, outcome pending.
CytoDyn appoints BF Borgers as auditor after MGO resignation
Audit Committee engaged BF Borgers CPA PC as independent auditor for FY ending May 31, 2024.
CytoDyn auditor MGO declines re-election for FY2024; no accounting disagreements
MGO declined to stand for re-election as CytoDyn's independent auditor for fiscal year 2024 on Sept 19, 2023.
CytoDyn discloses unregistered equity sales raising ~$3.5M with heavy dilution
Converted $2.0M of convertible note principal into ~9.8M shares via exchange; relied on Section 3(a)(9).
CytoDyn CEO resigns, returns as SVP; files $100M+ claim against former CRO Amarex
Dr. Cyrus Arman resigned as President and PEO on July 6, 2023; returns as SVP Business Operations with reduced salary of $300k.
CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed
Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.
CytoDyn raises $4.9M through private placement of 21.3M units at $0.23/unit
Proceeds of ~$4.9M from sale of ~21.3M units, each unit one share plus one warrant to purchase one share.
CytoDyn reports unregistered equity sales of ~$3.7M; President invests $100K
Private placement raised ~$3.6M from ~15.7M units at $0.23/unit; warrants exercisable at $0.50 for 5 years.
CytoDyn raises ~$7.9M in private placement; issues shares in note exchange
Exchanged $0.5M secured convertible note for 2.5M newly issued common shares on Jan 23, 2023.
CytoDyn CMO Scott A. Kelly resigns effective immediately
Scott A. Kelly, M.D., resigns as Chief Medical Officer of CytoDyn on December 19, 2022.
CytoDyn elects five directors, ratifies auditor, and approves say-on-pay at 2022 annual meeting
All five director nominees elected with 249M-252M votes for; broker non-votes of 191M.
Extends Indemnitors' surety bond obligation to Jan 31, 2023; must relieve $1.5M cash collateral by Jan 5, 2023, remaining $5M by Jan 31.
CytoDyn presents R&D update on December 7, 2022; no specific data disclosed
Company held an R&D Update and posted the presentation on its website.
CytoDyn CTO Nitya G. Ray resigns effective November 21, 2022
Nitya G. Ray, Ph.D., resigned as Chief Technology Officer effective immediately on November 21, 2022.
CytoDyn withdraws BLA for leronlimab in HIV-MDR citing CRO data issues
Voluntarily withdrew pending BLA for leronlimab as HIV combination therapy; FDA approval deemed not feasible due to CRO data quality issues.
CytoDyn director Scott Kelly resigns; Stephen Simes appointed to board.
Scott Kelly resigned as director effective Oct 13, 2022; remains CMO and Head of Business Development.
Shareholders approve increase in CytoDyn authorized shares from 1B to 1.35B
Stockholders voted 522,967,334 for, 19,601,702 against, 1,058,601 abstentions.
CytoDyn appoints Ryan Dunlap as director, effective Aug 25, 2022
Ryan Dunlap appointed as director, filling vacancy from Nader Pourhassan's Jan 2022 resignation.
CytoDyn restates FY2021 and five quarterly periods; prior financials no longer reliable
Audit Committee concludes FY2021 annual and five quarterly periods should not be relied upon.
CytoDyn raises $21.8M in private placement of units; corrects warrant exercise price to $0.30
Raised $21.8M gross via 85.4M units at $0.255/unit; each unit = one share + 0.75 warrant.
Warrant exercise price reduced from $0.30 to $0.20 per share for 30M shares of common stock.
CytoDyn raises $21.8M in private placement; appoints Cyrus Arman as President
Raised ~$21.8M gross via ~85.4M units at $0.255/unit; each unit = 1 share + 3/4 warrant (5-yr term).
CytoDyn raises ~$8.8M in private placement of 34.6M units with warrants
Raised $8,834,500 gross from ~34.6M units (1 share + 0.75 warrant) via placement agent.
CytoDyn settles former CMO suit, grants 8.3M shares & 7M warrants; board member resigns
Settlement with former CMO Richard Pestell resolves breach-of-contract lawsuit; CytoDyn relinquishes 8,342,000 shares and removes transfer restrictions.
CytoDyn raises ~$6.5M in unregistered equity offerings
Received subscription agreements for ~24.4M units (1 share + 3/4 warrant) from accredited investors via placement agent.
CytoDyn raises $4.8M via private placement of 17.6M units at 85% of VWAP
Issued 107,707 shares to former exec for $36,671 in severance satisfaction.
CytoDyn reorganizes management: Ray remains CTO, Recknor no longer executive officer
Nitya G. Ray, Ph.D., no longer COO; continues as Chief Technology Officer.
CytoDyn auditor Warren Averett resigns; MGO appointed as new auditor
Warren Averett resigned as CytoDyn's independent auditor effective April 13, 2022; audit committee did not recommend change.
CytoDyn issues 932,272 shares to two former executives for ~$0.5M severance
Issued 932,272 shares of common stock to two former executive officers as severance payments.
On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).
On January 26, 2024, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s Chief Executive Officer and will serve as its principal executive officer, effective as of January 26, 2024.
On January 10, 2024, the Company entered into an agreement with Rapid Deployment LLC d/b/a InterimExecs (“InterimExecs”), under which Mitchell Cohen will serve as the Company’s Interim CFO, effective February 1, 2024.
On January 23, 2024, Antonio Migliarese informed the Company that he would be resigning from his position as CFO, effective January 31, 2024.
On November 17, 2023, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with. Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s interim CEO on an at-will basis, effective November 17, 2023.
Antonio Migliarese, who was appointed as interim President on May 18, 2023, ceased being interim President on November 17, 2023, but will continue in his roles of Chief Financial Officer and Treasurer, as well as serving as the Company’s principal accounting officer.
Dr. Cyrus Arman, on medical leave since May 18, 2023, after serving as the President and principal executive officer of CytoDyn Inc. (the “Company”) since July 9, 2022, resigned as the Company’s President and principal executive officer on July 6, 2023, and returned to the Company as its Senior Vice President, Business Operations, a nonexecutive position in which he will work reduced hours, effective July 7, 2023.
On May 18, 2023, the Company’s Board of Directors appointed Antonio Migliarese as acting principal executive officer of the Company on an interim basis.
Dr. Cyrus Arman, President of CytoDyn Inc. (the “Company”) and the Company’s principal executive officer, recently informed the Company that he will be taking a medical leave of absence.
On December 19, 2022, the Company and Scott A. Kelly M.D., the Company’s Chief Medical Officer, agreed that Dr. Kelly will resign from his role at the Company, effective immediately.
On November 21, 2022, the Company and Nitya G. Ray, Ph.D., the Company’s Chief Technology Officer, agreed that Dr. Ray will resign from his role at the Company, effective immediately.
On October 13, 2022, the Company’s Board of Directors (the “Board”) approved the appointment of Stephen M. Simes (“Mr. Simes”) as a director of the Company, effective October 13, 2022.
Max materiality 0.85 · Median 0.60 · Most common event other_material